Pharma / Biotech

Management of Acute Coronary Syndrome Using Small-Molecule Glycoprotein IIb/IIIa Inhibitors: The Contemporary Role of Aggrastat (tirofiban hydrochloride) Injection for High-Risk Patients

This monograph discusses the current role of small-molecule GP IIb/IIa inhibitors in the management of patients at high risk for thrombotic events and describes the benefits of using Aggrastat (tirofiban hydrochloride) injection in customizing infusions for these patients.

Source link

Related posts

New Data Show 1-Hour Sepsis Bundle Works


pharmacokinetics; +159 new citations


ADENOSINE INJECTION, 6MG/2ML (3MG/ML) VIAL Injection, Solution [HF Acquisition Co. LLC, DBA Health First]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World